# Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Source: https://onco.cc/trials/nct05739981/  
OnCo record `nct05739981` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Carboplatin, Bevacizumab in ovarian cancer, run by Imunon, now recruiting.

## Summary

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer is a phase 1/2 interventional study registered as NCT05739981 by Imunon, with 30 participants planned, started 2023-02-10 and due to reach its primary completion in 2027-06-30. Interventions recorded: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05739981
- Phase: 1/2
- Setting: Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Sponsor: Imunon
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05739981: https://clinicaltrials.gov/study/NCT05739981

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Imunon](https://onco.cc/companies/imunon/)

---
JSON: https://onco.cc/api/v1/entities/nct05739981.json